Loading company
BeyondSpring Inc.
BYSI · Nasdaq · ·
Next earnings: November 11, 2026
$0.77-31.0%Sep 29 close
- 1M
- +28.3%
- 6M
- -54.8%
- 1Y
- -56.8%
- 5Y
- -95.0%
BYSI · Nasdaq · ·
Next earnings: November 11, 2026
$0.77-31.0%Sep 29 close
BeyondSpring Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$849K | -$1.8M | +52.99% |
| Profit per share | -$0.10 | -$0.49 | +79.59% |
| Free Cash Flow | -$3.8M | -$5.9M | +35.78% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter was marked by additional clinical and scientific support for continuing Plinabulin development,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet needs. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine . Plinabulin’s novel mechanism as a GEF-H1 agonist with dendritic cell maturation benefit supports both anticancer activity and immune modulation, offering a unique approach to re-sensitizing tumors resistant to checkpoint inhibitors. In addition, it has the potential to synergize with chemotherapy, antibody-drug conjugates (ADCs), radiation, and checkpoint inhibitors. Learn more at beyondspringpharma.com. Investor
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from BeyondSpring Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
BeyondSpring Inc. has no earnings call transcript available.